as 12-11-2024 4:00pm EST
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Founded: | 1967 | Country: | United States |
Employees: | N/A | City: | SECAUCUS |
Market Cap: | 17.5B | IPO Year: | 1996 |
Target Price: | $166.15 | AVG Volume (30 days): | 869.3K |
Analyst Decision: | Buy | Number of Analysts: | 13 |
Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
EPS: | 7.44 | EPS Growth: | 11.56 |
52 Week Low/High: | $123.04 - $165.32 | Next Earning Date: | 01-30-2025 |
Revenue: | $9,539,000,000 | Revenue Growth: | 2.60% |
Revenue Growth (this year): | 7.33% | Revenue Growth (next year): | 8.70% |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
PREVOZNIK MICHAEL E | DGX | SVP & General Counsel | Nov 29 '24 | Sell | $162.70 | 35,146 | $5,731,301.51 | 38,478 | |
DEPPE MICHAEL J | DGX | SVP, Corp. Controller & CAO | Nov 6 '24 | Sell | $153.82 | 18,755 | $2,889,122.88 | 45,061 | |
KUPPUSAMY KARTHIK | DGX | SVP, Clinical Solutions | Oct 28 '24 | Sell | $156.92 | 1,775 | $278,525.19 | 9,734 |
DGX Breaking Stock News: Dive into DGX Ticker-Specific Updates for Smart Investing
Zacks
8 days ago
PR Newswire
9 days ago
PR Newswire
9 days ago
MT Newswires
9 days ago
MT Newswires
9 days ago
Insider Monkey
14 days ago
Zacks
15 days ago
MT Newswires
17 days ago
The information presented on this page, "DGX Quest Diagnostics Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.